Assuntos
Institutos de Câncer , Neoplasias , Centros Médicos Acadêmicos , Objetivos , Humanos , Motivação , Neoplasias/terapia , Estados UnidosRESUMO
OBJECTIVE: Breast cancer survivors who experience psychological and physical symptoms after treatment have an increased risk for comorbid disease development, reduced quality of life, and premature mortality. Identifying factors that reduce or exacerbate their symptoms may enhance their long-term health and physical functioning. This study examined how survivors' marital status and marital satisfaction-key health determinants-impacted their psychological and physical health trajectories to understand when, and for whom, marriage offers health benefits. METHODS: Breast cancer survivors (n = 209, stages 0-IIIC) completed a baseline visit before treatment and two follow-up visits 6 and 18 months after treatment ended. Women completed questionnaires assessing their marital status and satisfaction when applicable, as well as their psychological (depressive symptoms, stress) and physical (fatigue, pain) health at each visit. RESULTS: Married women-both those in satisfying and dissatisfying marriages-experienced improvements in their depressive symptoms, stress, and fatigue from pretreatment to 6- and 18-month posttreatment. Unmarried (i.e., single, divorced/separated, or widowed) women's depressive symptoms, stress, fatigue, and pain did not change over time, instead remaining elevated 6 and 18 months after treatment ended. Women in satisfying marriages also had fewer psychological and physical symptoms after treatment than those who were unmarried or in dissatisfying marriages. CONCLUSIONS: Although marriage was associated with improved psychological and physical health, the gains were most notable when survivors' marriages were satisfying. Thus, the quality of survivors' marriages, rather than the marriage itself, provided the most benefits to their psychological and physical health.
Assuntos
Neoplasias da Mama , Sobreviventes de Câncer , Feminino , Humanos , Casamento , Satisfação Pessoal , Qualidade de Vida , Pessoa Solteira , SobreviventesRESUMO
BACKGROUND: Current recommendations for persistent or recurrent locoregional papillary thyroid cancer (PTC) include consideration of surgical resection versus active surveillance. The purpose of this study is to determine long-term outcomes after surgical resection of recurrent or persistent metastatic PTC in cervical lymph nodes after failure of initial surgery and radioactive iodine therapy using newer validated clinical outcomes measures. METHODS: Outcomes of 70 patients who underwent cervical lymphadenectomy (n = 110) from 1999 to 2013 for recurrent or persistent locoregional PTC metastases were reviewed. Measures included biochemical remission (BCR) based on Tg levels, American Thyroid Association classifications for response to treatment [biochemical incomplete response (BIR), structural incomplete response (SIR), indeterminate response (IR), and excellent response (ER)], need for reoperation, surgical complications, disease progression, and death. RESULTS: The median follow-up was 13.1 years, with only two additional reoperations since 2010, one of which had no metastasis on pathology with the other developing anaplastic thyroid cancer in background PTC. ER was achieved in 31 (44%) patients, all of whom remained in ER at time of last follow-up (median 14.1 years). There were no structural recurrences in patients with persistent BIR or IR after reoperation. Patients with SIR had stable disease, except for one who died due to anaplastic thyroid cancer. CONCLUSIONS: Patients who achieved ER after reoperation had no need for further treatment. Patients with persistent detectable Tg levels after reoperation rarely developed structural recurrence. ATA outcomes can be safely used to guide treatment decisions over a decade after reoperation for PTC.
Assuntos
Carcinoma Papilar/cirurgia , Radioisótopos do Iodo/efeitos adversos , Excisão de Linfonodo/efeitos adversos , Linfonodos/cirurgia , Cirurgia de Second-Look/métodos , Neoplasias da Glândula Tireoide/cirurgia , Tireoidectomia/efeitos adversos , Adolescente , Adulto , Idoso , Carcinoma Papilar/patologia , Carcinoma Papilar/terapia , Estudos de Coortes , Terapia Combinada , Estudos Transversais , Feminino , Seguimentos , Humanos , Linfonodos/patologia , Masculino , Pessoa de Meia-Idade , Reoperação , Taxa de Sobrevida , Neoplasias da Glândula Tireoide/patologia , Neoplasias da Glândula Tireoide/terapia , Fatores de Tempo , Resultado do Tratamento , Adulto JovemRESUMO
BACKGROUND: Prior to treatment, breast cancer patients are less physically fit compared to peers; during cancer treatment, their fitness typically declines. Depressive symptoms are associated with reduced activity up to 5 years post-treatment, but research has not identified mechanisms linking depression and lower activity. The current study assessed relationships among breast cancer patients' depression and perceived exertion during exercise as well as heart rate, an objective indicator of exertion. METHODS: Participants were 106 breast cancer patients, stages I-IIIA, who completed surgery but had not started adjuvant treatment. Heart rate and self-rated exertion, measured using the Borg Scale of Perceived Exertion, were assessed every 2 min during a graded exercise test. Depression was assessed using the CES-D and a structured clinical interview. RESULTS: Compared to women below the CES-D clinical cutoff, women with significant depressive symptoms reported steeper increases in exertion during the exercise test (p = .010) but had similar heart rates (p = .224) compared to women below the cutoff. Major depression history was unrelated to perceived exertion (ps > .224) and heart rate (ps > .200) during exercise. CONCLUSIONS: Women with currently elevated depressive symptoms experienced exercise as more difficult compared to women below the CES-D cutoff, but these self-perceptions did not reflect actual heart rate differences. Depression may make exercise feel more demanding, which could ultimately decrease patients' likelihood of engaging in regular exercise. Results support the use of depression screening tools following breast cancer surgery to identify and intervene on individuals at risk for decreased physical activity during survivorship.
Assuntos
Neoplasias da Mama/psicologia , Depressão/psicologia , Teste de Esforço/psicologia , Exercício Físico/psicologia , Adulto , Idoso , Emoções , Feminino , Frequência Cardíaca , Humanos , Pessoa de Meia-Idade , Percepção , AutoimagemRESUMO
These NCCN Guidelines Insights highlight the updated recommendations for use of multigene assays to guide decisions on adjuvant systemic chemotherapy therapy for women with hormone receptor-positive, HER2-negative early-stage invasive breast cancer. This report summarizes these updates and discusses the rationale behind them.
Assuntos
Neoplasias da Mama/diagnóstico , Neoplasias da Mama/terapia , Neoplasias da Mama/etiologia , Feminino , HumanosRESUMO
The NCCN Guidelines for Breast Cancer Screening and Diagnosis have been developed to facilitate clinical decision making. This manuscript discusses the diagnostic evaluation of individuals with suspected breast cancer due to either abnormal imaging and/or physical findings. For breast cancer screening recommendations, please see the full guidelines on NCCN.org.
Assuntos
Neoplasias da Mama/diagnóstico , Detecção Precoce de Câncer/normas , Programas de Rastreamento/normas , Oncologia/normas , Adulto , Fatores Etários , Biópsia/métodos , Biópsia/normas , Mama/diagnóstico por imagem , Mama/patologia , Neoplasias da Mama/epidemiologia , Neoplasias da Mama/patologia , Neoplasias da Mama/prevenção & controle , Tomada de Decisão Clínica/métodos , Detecção Precoce de Câncer/métodos , Feminino , Humanos , Incidência , Mamografia/métodos , Mamografia/normas , Programas de Rastreamento/métodos , Oncologia/métodos , Pessoa de Meia-Idade , Sociedades Médicas/normas , Estados Unidos/epidemiologiaRESUMO
PURPOSE: A meta-analysis of 22 randomized trials accrued from 1964 to 1986 demonstrated significantly higher rates of locoregional failure (LRF) and breast-cancer mortality in women with 1-3 positive nodes without postmastectomy radiotherapy (PMRT) after mastectomy (mast.). Recent data demonstrate that PMRT reduces distant metastases (DM) in women with pN1 disease. The challenge today is whether all patients with pathologic T1-2pN1 disease have similar substantial LRF/DM risk that routinely warrants PMRT. METHODS: We reviewed patients with pT1-2N1 breast cancer treated with mast. ± adjuvant systemic therapy without PMRT from 2000 to 2013. The endpoints were LRF and DM rates, estimated by cumulative incidence method. RESULTS: We identified 468 patients with median follow-up of 6.3 years. Most (71%) were estrogen receptor/progesterone receptor + human epidermal growth factor receptor 2 (HER2). There were 269 patients with 1+ node, 140 patients with 2+ nodes, and 59 patients with 3+ nodes. The 6-year LRF/DM rates were 4.1%/8.4%. Patients with 1+, 2+, and 3+ nodes had 6-year LRF of 2.3, 5.1 and 8.9%, respectively (p = 0.13). The 6-year DM rate was higher in patients with 3+ nodes versus 1-2+ nodes: 15.7% versus 7.4% (p = 0.02). Several subgroups had low 6-year LRF and DM rates, including T1/1+ node (0.8%/4.1% LRF/DM) and micrometastases (0%/5.8% LRF/DM). CONCLUSIONS: Patients with pT1-2pN1 represent a heterogeneous group with a wide range of LRF/DM rates. In particular, patients with pT1 tumors and 1 + LN, and patients with micrometastases, had low event rates. These groups would derive small absolute reductions in LRF and DM with addition of PMRT, underscoring the importance of patient selection for PMRT in pT1-2pN1 breast cancer.
Assuntos
Neoplasias da Mama/mortalidade , Linfonodos/patologia , Mastectomia/mortalidade , Recidiva Local de Neoplasia/epidemiologia , Radioterapia Adjuvante/mortalidade , Neoplasias da Mama/patologia , Neoplasias da Mama/radioterapia , Neoplasias da Mama/cirurgia , Terapia Combinada , Feminino , Seguimentos , Humanos , Incidência , Metástase Linfática , Pessoa de Meia-Idade , Invasividade Neoplásica , Recidiva Local de Neoplasia/mortalidade , Recidiva Local de Neoplasia/patologia , Estadiamento de Neoplasias , Ohio/epidemiologia , Estudos Retrospectivos , Taxa de Sobrevida , Resultado do TratamentoRESUMO
Ductal carcinoma in situ (DCIS) of the breast represents a heterogeneous group of neoplastic lesions in the breast ducts. The goal for management of DCIS is to prevent the development of invasive breast cancer. This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.
Assuntos
Neoplasias da Mama/diagnóstico , Neoplasias da Mama/terapia , Neoplasias da Mama/etiologia , Carcinoma Ductal de Mama/diagnóstico , Carcinoma Ductal de Mama/etiologia , Carcinoma Ductal de Mama/terapia , Carcinoma Intraductal não Infiltrante/diagnóstico , Carcinoma Intraductal não Infiltrante/etiologia , Carcinoma Intraductal não Infiltrante/terapia , Terapia Combinada , Gerenciamento Clínico , Feminino , Humanos , Retratamento , Resultado do Tratamento , Conduta ExpectanteRESUMO
Since 2007, the US National Cancer Institute (NCI) Office of Cancer Complementary and Alternative Medicine (OCCAM), together with the Cancer Institute of the China Academy of Chinese Medical Sciences (CICACMS), institutes at China Academy of Sciences and Chinese Academy of Medical Sciences, have engaged in collaborations on Chinese medicine (CM) and cancer research. Through these collaborations, CM drugs and compounds have been studied at NCI labs. This paper summarizes the discoveries and progress on these research projects, exploring the aspects of cancer prevention, botanical drug mechanisms of action and component analysis/quality control (QC), and anticancer activity screening. These and other related projects have been presented in various jointly convened workshops and have provided the backdrop for establishing a new organization, the International Consortium for CM and Cancer, to promote international collaborations in this field.
Assuntos
Medicina Tradicional Chinesa , Neoplasias/terapia , China , Medicamentos de Ervas Chinesas/química , Medicamentos de Ervas Chinesas/farmacologia , Medicamentos de Ervas Chinesas/uso terapêutico , Humanos , Medicina Tradicional Chinesa/métodos , National Cancer Institute (U.S.) , Neoplasias/diagnóstico , Neoplasias/prevenção & controle , Pesquisa , Estados UnidosRESUMO
These NCCN Guidelines Insights highlight the important updates/changes to the surgical axillary staging, radiation therapy, and systemic therapy recommendations for hormone receptor-positive disease in the 1.2017 version of the NCCN Guidelines for Breast Cancer. This report summarizes these updates and discusses the rationale behind them. Updates on new drug approvals, not available at press time, can be found in the most recent version of these guidelines at NCCN.org.
Assuntos
Neoplasias da Mama/diagnóstico , Neoplasias da Mama/terapia , Axila , Terapia Combinada/métodos , Gerenciamento Clínico , Feminino , Humanos , Estadiamento de Neoplasias , Biópsia de Linfonodo SentinelaRESUMO
OBJECTIVE: The aim of this study was to determine the impact of the results of the 12-gene DCIS Score assay on (i) radiotherapy recommendations for patients with pure ductal carcinoma in situ (DCIS) following breast-conserving surgery (BCS), and (ii) patient decisional conflict and state anxiety. METHODS: Thirteen sites across the US enrolled patients (March 2014-August 2015) with pure DCIS undergoing BCS. Prospectively collected data included clinicopathologic factors, physician estimates of local recurrence risk, DCIS Score results, and pre-/post-assay radiotherapy recommendations for each patient made by a surgeon and a radiation oncologist. Patients completed pre-/post-assay decisional conflict scale and state-trait anxiety inventory instruments. RESULTS: The analysis cohort included 127 patients: median age 60 years, 80 % postmenopausal, median size 8 mm (39 % ≤5 mm), 70 % grade 1/2, 88 % estrogen receptor-positive, 75 % progesterone receptor-positive, 54 % with comedo necrosis, and 18 % multifocal. Sixty-six percent of patients had low DCIS Score results, 20 % had intermediate DCIS Score results, and 14 % had high DCIS Score results; the median result was 21 (range 0-84). Pre-assay, surgeons and radiation oncologists recommended radiotherapy for 70.9 and 72.4 % of patients, respectively. Post-assay, 26.4 % of overall recommendations changed, including 30.7 and 22.0 % of recommendations by surgeons and radiation oncologists, respectively. Among patients with confirmed completed questionnaires (n = 32), decision conflict (p = 0.004) and state anxiety (p = 0.042) decreased significantly from pre- to post-assay. CONCLUSIONS: Individualized risk estimates from the DCIS Score assay provide valuable information to physicians and patients. Post-assay, in response to DCIS Score results, surgeons changed treatment recommendations more often than radiation oncologists. Further investigation is needed to better understand how such treatment changes may affect clinical outcomes.
Assuntos
Neoplasias da Mama/genética , Neoplasias da Mama/radioterapia , Carcinoma Intraductal não Infiltrante/genética , Carcinoma Intraductal não Infiltrante/radioterapia , Perfilação da Expressão Gênica , Adulto , Idoso , Idoso de 80 Anos ou mais , Ansiedade/etiologia , Neoplasias da Mama/cirurgia , Carcinoma Intraductal não Infiltrante/cirurgia , Tomada de Decisão Clínica , Conflito Psicológico , Feminino , Humanos , Mastectomia Segmentar , Pessoa de Meia-Idade , Padrões de Prática Médica , Radio-Oncologistas , Radioterapia Adjuvante , Medição de Risco/métodos , Cirurgiões , Inquéritos e QuestionáriosRESUMO
Purpose The sequelae of cancer treatment may increase systemic inflammation and create a phenotype at increased risk of functional decline and comorbidities, leading to premature mortality. Little is known about how this trajectory compares with natural aging among peers of the same age without cancer. This longitudinal study investigated proinflammatory cytokines and comorbidity development over time among breast cancer survivors and a noncancer control group. Methods Women (N = 315; 209 with breast cancer and 106 in the control group) were recruited at the time of their work-up for breast cancer; they completed the baseline questionnaire, interview, and blood draw (lipopolysaccharide-stimulated production of interleukin [IL] -6, tumor necrosis factor-α, and IL-1ß). Measures were repeated 6 and 18 months after primary cancer treatment (cancer survivors) or within a comparable time frame (control group). Results There were no baseline differences in comorbidities or cytokines between survivors and the control group. Over time, breast cancer survivors had significantly higher tumor necrosis factor-α and IL-6 compared with the control group. Survivors treated with surgery, radiation, and chemotherapy accumulated a significantly greater burden of comorbid conditions and suffered greater pain associated with inflammation over time after cancer treatment than did the control group. Conclusion Survivors who had multimodal treatment had higher cytokines and comorbidities, suggestive of accelerated aging. Comorbidities were related to inflammation in this sample, which could increase the likelihood of premature mortality. Given that many comorbidities take years to develop, future research with extended follow-up beyond 18 months is necessary to examine the evidence of accelerated aging in cancer survivors and to determine the responsible mechanisms.
Assuntos
Senilidade Prematura/etiologia , Neoplasias da Mama/terapia , Neoplasias da Mama/sangue , Neoplasias da Mama/complicações , Neoplasias da Mama/mortalidade , Terapia Combinada , Comorbidade , Citocinese/fisiologia , Feminino , Humanos , Interleucina-1beta/sangue , Interleucina-6/sangue , Estudos Longitudinais , Pessoa de Meia-Idade , Fator de Necrose Tumoral alfa/sangueRESUMO
Recent evidence indicates that tumor-initiating cells (TICs), also called cancer stem cells (CSCs), are responsible for tumor initiation and progression, therefore representing an important cell population that may be used as a target for the development of future anticancer therapies. In the present study, Cryptotanshinone (CT), a traditional Chinese herbal medicine, was demonstrated to regulate the behaviors of LNCaP prostate cells and prostate LNCaP TICs. The results demonstrate that treatment with CT alters cellular proliferation, cell cycle status, migration, viability, colony formation and notably, sphere formation and down-regulation of stemness genes (Nanog, OCT4, SOX2, ß-catenin, CXCR4) in TICs. The present study demonstrates that CT targets the LNCaP CD44+CD24- population that is representative of prostate TICs and also affects total LNCaP cells as well via down-regulation of stemness genes. The strong effect with which CT has on prostate TICs suggests that CT may potentially function as a novel natural anticancer agent that specifically targets TICs.
RESUMO
Breast cancer is the most common malignancy in women in the United States and is second only to lung cancer as a cause of cancer death. The overall management of breast cancer includes the treatment of local disease with surgery, radiation therapy, or both, and the treatment of systemic disease with cytotoxic chemotherapy, endocrine therapy, biologic therapy, or combinations of these. This article outlines the NCCN Guidelines specific to breast cancer that is locoregional (restricted to one region of the body), and discusses the management of clinical stage I, II, and IIIA (T3N1M0) tumors. For NCCN Guidelines on systemic adjuvant therapy after locoregional management of clinical stage I, II and IIIA (T3N1M0) and for management for other clinical stages of breast cancer, see the complete version of these guidelines at NCCN.org.
Assuntos
Neoplasias da Mama/patologia , Neoplasias da Mama/terapia , Quimioterapia Adjuvante/efeitos adversos , Terapia Combinada , Feminino , Fertilidade/efeitos dos fármacos , Preservação da Fertilidade , Humanos , Mamoplastia/métodos , Mastectomia/métodos , Invasividade Neoplásica , Estadiamento de Neoplasias , Radioterapia Adjuvante/efeitos adversos , Estados UnidosRESUMO
These NCCN Guideline Insights highlight the important updates to the systemic therapy recommendations in the 2016 NCCN Guidelines for Breast Cancer. In the most recent version of these guidelines, the NCCN Breast Cancer Panel included a new section on the principles of preoperative systemic therapy. In addition, based on new evidence, the panel updated systemic therapy recommendations for women with hormone receptor-positive breast cancer in the adjuvant and metastatic disease settings and for patients with HER2-positive metastatic breast cancer. This report summarizes these recent updates and discusses the rationale behind them.
Assuntos
Neoplasias da Mama/terapia , Feminino , HumanosRESUMO
BACKGROUND: Increased emphasis has been placed on process outcomes for breast cancer care, but limited data exists on these measures for breast reconstruction. These processes are likely to be impacted by increased centralization of care into comprehensive breast centers (CBC). Our study objectives were to define measures for processes of care in breast reconstruction and to determine the effect of a CBC on these measures. METHODS: A 5-year review was performed of patients who underwent mastectomy with or without reconstruction for a newly diagnosed breast cancer between 2010 and 2014, which spans from 1 year before to 4 years after introduction of our CBC. RESULTS: A total of 4179 patients were reviewed. The referral rate for immediate reconstruction increased from 40.0 to 70.8 % (p < .001), and the immediate reconstruction rate increased from 36.7 to 65.0 % (p < .001), both plateauing in the fourth study year. The interval between surgical oncology and plastic surgery consultation decreased (from 9.2 to 2.5 days; p < .001), and stabilized in the second study year. The interval between plastic surgery consultation and surgery decreased throughout the entire study period (from 37.6 to 20.8 days; p < .001), resulting in continued improvements in the interval between surgical oncology consultation and surgery (from 46.8 to 23.3 days, p < .001). CONCLUSIONS: In breast reconstruction, a CBC results in improvements in process outcomes, some of which are realized in the short-term and others in the long-term. The timeliness of treatment of patients who undergo immediate postmastectomy reconstruction can be similar to targets set for patients who undergo mastectomy alone.
Assuntos
Neoplasias da Mama/cirurgia , Institutos de Câncer/organização & administração , Assistência Integral à Saúde/métodos , Mamoplastia/métodos , Mastectomia/métodos , Neoplasias da Mama/patologia , Feminino , Humanos , Estadiamento de Neoplasias , Avaliação de Resultados em Cuidados de Saúde , Prognóstico , Melhoria de Qualidade , Encaminhamento e Consulta , Estudos RetrospectivosRESUMO
Breast cancer is the most common malignancy in women in the United States and is second only to lung cancer as a cause of cancer death. The overall management of breast cancer includes the treatment of local disease with surgery, radiation therapy, or both, and the treatment of systemic disease with cytotoxic chemotherapy, endocrine therapy, biologic therapy, or combinations of these. This portion of the NCCN Guidelines discusses recommendations specific to the locoregional management of clinical stage I, II, and IIIA (T3N1M0) tumors.
Assuntos
Neoplasias da Mama/patologia , Neoplasias da Mama/terapia , Excisão de Linfonodo , Mastectomia , Axila , Neoplasias da Mama/diagnóstico , Feminino , Humanos , Mamoplastia , Mastectomia/métodos , Estadiamento de Neoplasias , RadioterapiaRESUMO
BACKGROUND: Processes outcomes for breast reconstruction (related to access, efficiency, and sustainability) have not been well described. These processes are likely to be impacted by the centralization of breast cancer care into comprehensive breast centers. The authors' study objectives were to define measures for breast reconstruction processes of care and to determine a breast center's effect on these measures. METHODS: All patients evaluated for postmastectomy breast reconstruction between 2009 and 2013 (2 years before to 2 years after opening of the authors' breast center) were reviewed. Consultation, surgical, and financial data were compared between the two periods. RESULTS: A total of 614 (45.0 percent) and 750 patients (55.0 percent) were treated before and after, respectively, formation of the authors' breast center. Between the two periods, the internal referral rate for postmastectomy reconstruction increased from 27.1 percent to 46.0 percent (p<0.001). The delay between surgical oncology and plastic surgery consultation decreased from 10.5 days to 3.6 days (p<0.001), as did the delay between plastic surgery consultation and surgery for both autologous (from 45.1 days to 32.6 days; p=0.003) and implant-based reconstruction (from 34.9 days to 25.5 days; p=0.004). The immediate breast reconstruction rate increased from 40.1 percent to 52.7 percent (p<0.001), including autologous reconstruction (from 13.1 percent to 20.8 percent; p<0.001). CONCLUSIONS: In breast reconstruction, a comprehensive breast center improves processes of care. The authors describe their strategy for integration of reconstructive surgery into a breast center.
Assuntos
Neoplasias da Mama/cirurgia , Institutos de Câncer/organização & administração , Assistência Integral à Saúde/métodos , Mamoplastia/métodos , Avaliação de Resultados em Cuidados de Saúde , Adulto , Idoso , Neoplasias da Mama/mortalidade , Neoplasias da Mama/patologia , Distribuição de Qui-Quadrado , Estudos de Coortes , Feminino , Acessibilidade aos Serviços de Saúde , Humanos , Mamoplastia/efeitos adversos , Mastectomia/efeitos adversos , Mastectomia/métodos , Pessoa de Meia-Idade , Melhoria de Qualidade , Estudos Retrospectivos , Taxa de Sobrevida , Resultado do Tratamento , Estados UnidosRESUMO
A substantial number of cancer patients experience depression. This study investigated treatment preferences for depression. Breast cancer survivors (N = 134) completed an anonymous survey asking preference and interest in three treatments for depression: individual counseling (IC), antidepressant medication (MED), or support groups (SG). Participants were recruited from a surgical oncology office and asked to complete the survey as they waited for their appointment. Preference was compared using Wilcoxon Signed Ranks tests. More than 50% ranked IC as first choice of treatment. Preference for IC was significantly higher than preference for MED and SG. Preference between MED and SG did not differ. Survivors prefered counseling for treatment of depression. Cancer centers should be prepared to provide preferred treatment methods, particulary as screening, and therefore management, of psychosocial distress is to be required.
Assuntos
Neoplasias da Mama/psicologia , Aconselhamento/métodos , Depressão/terapia , Preferência do Paciente/estatística & dados numéricos , Sobreviventes/psicologia , Idoso , Antidepressivos/uso terapêutico , Depressão/psicologia , Feminino , Pesquisas sobre Atenção à Saúde , Humanos , Pessoa de Meia-Idade , Psicoterapia/métodos , Grupos de Autoajuda , Estresse Psicológico/psicologia , Sobreviventes/estatística & dados numéricosRESUMO
Attachment theory provides a framework for understanding individual differences in chronic interpersonal stress. Attachment anxiety, a type of relationship insecurity characterized by worry about rejection and abandonment, is a chronic interpersonal stressor. Stress impacts cellular immunity, including herpesvirus reactivation. We investigated whether attachment anxiety was related to the expression of a latent herpesvirus, Epstein-Barr virus (EBV), when individuals were being tested for breast or colon cancer and approximately 1 year later. Participants (N=183) completed a standard attachment questionnaire and provided blood to assess EBV viral capsid antigen (VCA) IgG antibody titers. Individuals with more attachment anxiety had higher EBV VCA IgG antibody titers than those with less attachment anxiety. The strength of the association between attachment anxiety and antibody titers was the same at both assessments. This study is the first to show an association between latent herpesvirus reactivation and attachment anxiety. Because elevated herpesvirus antibody titers reflect poorer cellular immune system control over the latent virus, these data suggest that high attachment anxiety is associated with cellular immune dysregulation.